CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Cipro In Dextrose 5% In Plastic Container, and when can generic versions of Cipro In Dextrose 5% In Plastic Container launch?

Cipro In Dextrose 5% In Plastic Container is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER is ciprofloxacin. There are thirty-four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ciprofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cipro In Dextrose 5% In Plastic Container

A generic version of CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as ciprofloxacin by HIKMA FARMACEUTICA on December 22^nd, 2009.

Summary for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019857-001	Dec 26, 1990		DISCN	Yes	No
Bayer Hlthcare	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019857-002	Dec 26, 1990		DISCN	Yes	No

International Patents for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

See the table below for patents covering CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0219784	INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-CHINOLON-3-CARBOXYLIC ACID
Ireland	812032
Portugal	79206	PROCESS FOR PREPARING SOLUTIONS OF LACTIC ACID SALTS OF PIPERAZINILQUINOLON- AND PIPERAZINIL-AZAQUINOLONE-CARBOXYLIC ACIDS
Cyprus	1301	7-AMINO-1-CYCLOPROPYL-4-OXO-1,4-DIHYDRO-NAPHTHYRIDINE(-QUINOLINE)-3-CARBOXYLIC ACIDS,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Supplementary Protection Certificates for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003

Investment Scenario, Market Dynamics, and Financial Trajectory for CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

Last updated: February 3, 2026

Summary

Cipro in dextrose 5% in a plastic container represents a broad category within injectable antibiotics, specifically ciprofloxacin formulations. Currently, the global intravenous (IV) antibiotics market is expanding due to rising hospitalizations, increased antimicrobial resistance, and growth in surgical procedures. The product's potential hinges on regulatory approval, manufacturing capacity, market competition, and pricing strategies. This report analyzes the current market context, growth prospects, and financial outlook for Cipro in dextrose 5%, guiding stakeholders in investment and strategic decisions.

---

1. What is the Market Size and Demand for Ciprofloxacin in Dextrose 5%?

Global Intravenous Antibiotics Market Overview

Metric	Data	Source
Market size (2022)	$7.8 billion	Grand View Research[1]
Projected CAGR	3.9% (2023-2030)	Grand View Research[1]
Key segments	Fluoroquinolones, carbapenems, aminoglycosides	Market estimates
Major regions	North America, Europe, Asia-Pacific	MarketReportsWorld[2]

Ciprofloxacin Market Analysis

Parameter	Details
Current global sales of ciprofloxacin (injectable + oral)	$1.2 billion (est., 2022)	IQVIA[3]
Declared indications	Respiratory infections, urinary tract infections, intra-abdominal infections	product literature
Number of formulations	Oral (tablet, syrup), injectable (IV)	product data

Growth Drivers

• Rising prevalence of bacterial infections, notably multi-drug resistant (MDR) strains
• Increased hospitalization rates for infectious diseases
• Rising surgical procedures requiring prophylactic antibiotics
• Growing adoption of IV therapies in outpatient settings
• Pandemic-induced focus on infection control

Key Markets

Region	Market Share (2022)	Growth Potential	Regulatory Environment
North America	40%	High, due to advanced healthcare infrastructure	Favorable (FDA approvals)
Europe	25%	Steady	Stringent, well-regulated
Asia-Pacific	25%	Rapid growth	Evolving regulations, emerging markets
Rest of world	10%	Moderate	Varies, less mature

---

2. How Do Market Dynamics Influence the Financial Outlook?

Competitive Landscape

Competitor	Product	Formulation	Market Share	Key Differentiators
Bayer	Cipro (oral, injectable)	IV and oral	Leading	Established brand, global presence
Sandoz	Ciprofloxacin injection	Generic	Significant	Price competitiveness
Teva	Ciprofloxacin	Generic	Growing	Cost efficiency

Pricing and Reimbursement

• Pricing: Prices vary according to formulation, region, and market maturity. Approximate cost for a 100 mL vial: $10–$20 (generics).
• Reimbursement: Varies greatly; high in North America and Europe; emerging markets show variability.

Regulatory Considerations

• FDA & EMA Approval: Necessary for market entry in the US and Europe
• Orphan or Infectious Disease Designations: May influence approval timelines and patent extensions
• Patent Life: Typically 20 years from filing, with exclusivity periods affecting market share

Market Challenges

• Antibiotic stewardship leading to restricted use
• Growing concern over antimicrobial resistance (AMR)
• Stringent regulatory policies to curb resistance

Opportunities

• Developing formulations for specific indications
• Targeting emerging markets with unmet needs
• Formulation innovation (e.g., pre-filled syringes, stability improvements)

---

3. What Are the Financial Projections and Investment Scenarios?

Assumptions

Parameter	Value
Estimated production cost per 100 mL vial	$2–$4
Target selling price	$10–$15
Estimated market penetration (Year 1)	2% of global IV ciprofloxacin sales
Growth rate (post-launch sales)	10–15% annually in targeted regions
Regulatory approval timeline	12–24 months

Revenue Projections (Base Case)

Year	Global Market Size (USD)	Estimated Share	Revenue (USD)	Notes
Year 1	$7.8 billion	0.1%	$7.8 million	Assuming 2% market share of ciprofloxacin IV segment
Year 3	$9.3 billion	0.3%	$27.9 million	Growth via expanded indication approvals
Year 5	$11.5 billion	0.5%	$57.5 million	Increased adoption and branding

Investment Cost Breakdown

Item	Estimated Cost (USD)	Notes
R&D & Clinical Trials	$50–$100 million	Depending on approval pathway
Regulatory Submission & Approval	$10–$20 million	Per region
Manufacturing Setup	$20–$50 million	Equipment, validation
Marketing & Distribution	$10–$30 million	Regional campaigns

Profitability Outlook

Metric	Year 1	Year 3	Year 5
Gross Margin	60–70%	65–75%	70–80%
EBITDA	Break-even (initial)	Positive	Increasing margins

Risks and Uncertainties

Risk Factor	Impact	Mitigation Strategies
Regulatory delays	High	Early engagement with authorities
Market competition	Moderate	Differentiation, strategic pricing
Resistance development	High	Stewardship programs, combination therapies

---

4. How Does Product Formulation Influence Market Adoption?

• Packaging: Plastic containers are standard; innovations include tamper-evidence and pre-filled syringes.
• Stability: Ciprofloxacin in dextrose 5% requires stability data; stability influences shelf life and handling.
• Administration: Compatibility with infusion pumps critical for hospital use.
• Compliance: Easy-to-use packaging increases hospital adoption.

---

5. Comparing CIPRO IN DEXTROSE 5% WITH Similar Formulations

Formulation	Volume	Concentration	Specialty	Price Range (USD)	Remarks
CIPRO IN DEXTROSE 5%	100 mL	Ciprofloxacin 200 mg	IV infusion	$10–$15	Established, generic options
CIPRO IN NORMAL SALINE	100 mL	200 mg	Prevalent alternative	Similar	Slight stability variations
Innovative delivery systems	Variable	Variable	Focus on stability & administration	Higher	Potential premium pricing

---

Key Market Trends and Policy Considerations

Trend	Implication	Policy Shift
AMR challenge	High demand for effective antibiotics	Incentives for novel formulations
Emphasis on sustainable healthcare	Cost-effective formulations favored	Price negotiations, formularies
Increase in outpatient IV therapy	Need for portable, stable formulations	Packaging and stability innovations

---

Key Takeaways

• The market for intravenous ciprofloxacin in dextrose 5% is growing, driven by rising infectious disease burdens and surgical procedures.
• Estimated global sales could reach approximately $58 million in five years under optimistic market penetration assumptions.
• Competitive landscape is dominated by generics, necessitating differentiated formulations or branding for market share capture.
• Regulatory and antimicrobial resistance challenges present significant hurdles but also opportunities for innovation.
• Cost management, stability, and ease of administration are critical success factors.
• Strategic regional focus, particularly in emerging markets, could accelerate growth.

---

FAQs

Q1: What regulatory pathways are available for bringing CIPRO IN DEXTROSE 5% to market?
A1: Regulatory pathways include New Drug Application (NDA) via FDA, Marketing Authorization Application (MAA) via EMA, and equivalents in other jurisdictions. Orphan drug status and fast-track designations may apply if targeting specific indications.

Q2: How does antimicrobial resistance affect the market outlook for ciprofloxacin formulations?
A2: Rising resistance limits the clinical utility of ciprofloxacin, reducing prescribing and revenue. However, formulations targeting resistant strains or combination therapies could counteract this trend.

Q3: What are the primary cost elements in developing CIPRO IN DEXTROSE 5%?
A3: Key costs include R&D, clinical trials, regulatory submissions, manufacturing setup, validation, marketing, and distribution.

Q4: Which regions present the most attractive investment opportunities?
A4: North America and Europe provide high margins and regulatory clarity, while Asia-Pacific offers rapid growth potential with emerging markets.

Q5: What are the primary risks associated with investment in this product?
A5: Risks include regulatory delays, market competition, antimicrobial resistance, pricing pressures, and changes in healthcare policies.

---

References

[1] Grand View Research, "Intravenous Antibiotics Market Size, Share & Trends Analysis Report," 2022.
[2] MarketReportsWorld, "Global Antibiotics Market Assessment," 2021.
[3] IQVIA, "Global Antibiotics Sales Data," 2022.